Houston is one of only five WeWork Labs markets that can expect access to 3D printers as a part of a pilot program with two companies. Courtesy of WeWork

WeWork has teamed up with two leading 3D printing companies to bring their technology into five WeWork Labs markets — including Houston's downtown location. The other locations tapped for the pilot program are London, San Francisco, New York, and Seattle.

Massachusetts-based Formlabs' Form 2 printer has over 20 different material resins WeWork Labs members can use to prototype and print products using desktop stereolithography.

"Formlabs was founded eight years ago on the basis of empowering anyone to make anything," says Max Lobovsky, CEO and co-founder of Formlabs in a release. "Today, our customers have printed more than 40 million parts, they vary from early stage entrepreneurs changing the status quo and developing new applications to Fortune 500s experimenting with new business models or production methods."

The other company involved in the program is Seattle-based Glowforge, which created a 3D laser printer. Glowforge Plus uses subtractive laser technology to cut and sculpt projects from materials like wood, leather, acrylic, stone — and even stickers. The company, which was founded in 2014, has had over three million prints on its devices — everything from jewelry and clothing to machinery.

"We are thrilled to partner with WeWork Labs to provide their community of entrepreneurs and startups alike access to the tools that will help them create corporate giveaways, new product prototypes, and full production runs — everything to take their dreams from idea to creation," says Dan Shapiro, CEO of Glowforge, in the release.

The printers will be revealed at various launch events celebrating the National Week of Making, which begins June 21 and goes through June 27. Houston's launch event will be on June 28, but the specifics have not yet been finalized.

"We see WeWork Labs as a platform for creators, innovators and makers alike, and believe partnering with Glowforge and Formlabs will give our members even more of an opportunity to take their ideas, and bring them to life," says Katie Perkins, creative director at WeWork Labs, in the release. "We are incredibly excited to welcome two leading brands and their products into our community, giving creators access to the tools they need and inspiring new creators to be makers themselves."

Houston's WeWork Labs program launched in March in the WeWork Jones Building at 708 Main St. and includes a partnership with local digital startup resource, Alice. The WeWork Labs program started a little over a year ago and is already in over 30 markets worldwide.

"As the fourth largest city, Houston is in a unique position to launch high-impact startups," says Houston Labs Manager Carlos Estrada, in a previous release. "We see WeWork Labs in Houston as a tremendous platform for innovation, as our founder-focused approach to supporting early-stage startups will nurture and accelerate the work of entrepreneurs to scale their solutions to today's biggest challenges."

Form 2

Courtesy of WeWork

Using 20 types of resin materials, Formlabs' Form 2 can create parts or prototypes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”